Robotic-assisted retroperitoneal lymph node dissection for testicular cancer.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
8
6
2023
pubmed:
5
4
2023
entrez:
4
4
2023
Statut:
ppublish
Résumé
Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) is an emerging surgical option for testicular cancer with less morbidity than open RPLND. We outline the operative technique used at our center and review contemporary evidence in the advancement of R-RPLND. R-RPLND is being applied effectively beyond clinical stage I testicular cancer to treat low-volume, clinical stage II disease in both the primary and postchemotherapy setting. Compared with the open approach, R-RPLND offers shorter hospitalization and less blood loss with comparably low complications and oncologic control. With ongoing adoption and optimization of R-RPLND, future studies will assess long-term oncologic outcomes and disseminate R-RPLND in the treatment of testicular cancer.
Identifiants
pubmed: 37014761
doi: 10.1097/MOU.0000000000001094
pii: 00042307-202307000-00006
doi:
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-280Subventions
Organisme : NCI NIH HHS
ID : R01 CA241758
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA259173
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA273031
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Pishgar F, Haj-Mirzaian A, Ebrahimi H, et al. Global, regional and national burden of testicular cancer, 1990-2016: results from the Global Burden of Disease Study 2016. BJU Int 2019; 124:386–394.
Bleyer A, Barr R. Cancer in young adults 20 to 39 years of age: overview. Semin Oncol 2009; 36:194–206.
Hiester A, Che Y, Lusch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 2022; [Epub ahead of print].
Daneshmand S, Cary C, Masterson TA, et al. SEMS trial: result of a prospective, multiinstitutional phase II clinical trial of surgery in early metastatic seminoma. J Clin Oncol 2021; 39:375–1375.
Heidenreich A, Paffenholz P, Nestler T, et al. Nerve sparing retroperitoneal lymph node dissection in clinical stage IIA/B seminoma: the COTRIMS trial. J Clin Oncol 2022; 40:418–1418.
National Comprehensive Cancer Network. Testicular cancer (Version 1.2023), https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf [Accessed 2 February 2023].
Chovanec M, Abu Zaid M, Hanna N, et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol Off J Eur Soc Med Oncol 2017; 28:2670–2679.
Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 1992; 148:1907–1909.
Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 2006; 67:199.
Rodrigues GJ, Guglielmetti GB, Orvieto M, et al. Robot-assisted retroperitoneal lymphadenectomy: the state of art. Asian J Urol 2021; 8:27–37.
Rassweiler JJ, Scheitlin W, Heidenreich A, et al. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol 2008; 54:1004–1019.
Bhanvadia R, Ashbrook C, Bagrodia A, et al. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. World J Urol 2021; 39:1977–1984.
Ray S, Pierorazio PM, Allaf ME. Primary and postchemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review. Transl Androl Urol 2020; 9:949–958.
McClintock G, Goolam AS, Perera D, et al. Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer. Asian J Urol 2022; 204:1242–1248.
Ohlmann C-H, Saar M, Pierchalla L-C, et al. Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours. Sci Rep 2021; 11:10700.
Ghoreifi A, Mitra AP, McClintock G, et al. Robotic postchemotherapy retroperitoneal lymph node dissection for testicular cancer: a multicenter collaborative study. Urol Oncol Semin Orig Investig 2022; 41:111.e7–111.e14.
Pearce SM, Golan S, Gorin MA, et al. Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Eur Urol 2017; 71:476–482.
Stepanian S, Patel M, Porter J. Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique. Eur Urol 2016; 70:661–667.
Basourakos SP, Zhu A, Lewicki PJ, et al. Outpatient robotic assisted retroperitoneal lymph node dissection. Urol Case Rep 2022; 45:102192.
Basourakos SP, Zhu A, Lewicki PJ, et al. Clipless robotic-assisted radical prostatectomy and impact on outcomes. Eur Urol Focus 2022; 8:1176–1185.
Zhu A, Basourakos SP, Hu JC. Nerve-sparing techniques during robot-assisted radical prostatectomy: clips. Eur Urol Open Sci 2022; 44:104–105.
Pierorazio PM, Cheaib JG, Patel HD, et al. Comparative effectiveness of surveillance, primary chemotherapy, radiotherapy and retroperitoneal lymph node dissection for the management of early stage testicular germ cell tumors: a systematic review. J Urol 2021; 205:370–382.
Hudolin T, Kastelan Z, Knezevic N, et al. Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol 2012; 20:15–18.
Hale GR, Teplitsky S, Truong H, et al. Lymph node imaging in testicular cancer. Transl Androl Urol 2018; 7:864–874.
Neuenschwander A, Lonati C, Antonelli L, et al. Treatment outcomes for men with clinical stage II nonseminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: a systematic review. Eur Urol Focus 2022; [Epub ahead of print].
Taylor J, Becher E, Wysock JS, et al. Primary robot-assisted retroperitoneal lymph node dissection for men with nonseminomatous germ cell tumor: experience from a multiinstitutional cohort. Eur Urol Focus 2021; 7:1403–1408.
Williams SB, McDermott DW, Winston D, et al. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 2010; 105:918–921.
Subramanian VS, Nguyen CT, Stephenson AJ, et al. Complications of open primary and postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 2010; 28:504–509.
Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015; 33:51–57.
Fankhauser CD, Afferi L, Stroup SP, et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol 2022; 40:1505–1512.
Mistretta FA, de Cobelli O, Verze P, et al. A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. Asian J Androl 2022; 24:579–583.
Sigg S, Heidenreich A, Papachristofilou A, et al. How much chemotherapy is required to optimise long-term outcomes in clinical stage 2 seminoma? Eur Urol 2023; [Epub ahead of print].
Ruf CG, Krampe S, Matthies C, et al. Major complications of postchemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature. World J Surg Oncol 2020; 18:253.
Macleod LC, Rajanahally S, Nayak JG, et al. Characterizing the morbidity of postchemotherapy retroperitoneal lymph node dissection for testis cancer in a national cohort of privately insured patients. Urology 2016; 91:70–76.
Abdul-Muhsin H, Rocco N, Navaratnam A, et al. Outcomes of postchemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multiinstitutional study. World J Urol 2021; 39:3833–3838.
Grenabo Bergdahl A, Månsson M, Holmberg G, et al. Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centre. BJUI Compass 2022; 3:363–370.
Lloyd P, Hong A, Furrer MA, et al. A comparative study of peri-operative outcomes for 100 consecutive postchemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World J Urol 2022; 40:119–126.
Hiester A, Nini A, Fingerhut A, et al. Preservation of ejaculatory function after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testicular cancer: template vs. bilateral resection. Front Surg 2018; 5:80.
Pearce AK, Manson-Bahr D, Reid A, et al. Outcomes of postchemotherapy retroperitoneal lymph node dissection from a high-volume UK centre compared with a national data set. Eur Urol Open Sci 2021; 33:83–88.
Schermerhorn SMV, Christman MS, Rocco NR, et al. Learning curve for robotic-assisted laparoscopic retroperitoneal lymph node dissection. J Endourol 2021; 35:1483–1489.
Calaway AC, Einhorn LH, Masterson TA, et al. Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer. Eur Urol 2019; 76:607–609.
Porter J, Eggener S, Castle E, et al. Recurrence after robotic retroperitoneal lymph node dissection raises more questions than answers. Eur Urol 2019; 76:610–611.
Nason GJ, Jewett MAS, Hamilton RJ, et al. Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer. Eur Urol 2019;76:607-9. Eur Urol 2019; 76:e139–e140.
Williams SB, Ray-Zack MD, Hudgins HK, et al. Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review. Eur Urol Oncol 2019; 2:265–273.
Woldu SL, Matulay JT, Clinton TN, et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol Semin Orig Investig 2018; 36:14.e7–14.e15.